Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib with Durvalumab and Tremelimumab in unresectable HCC
NCT06698250Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zanzalintinib in hepatocellular carcinoma (HCC) (3 arms). Primary endpoints: Recommended Phase 2 Dose at 12 months and Objective Response Rate by imRECIST at 24 months. Started Dec 2024; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06698250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698250.